The High-Stakes World of Biotech
Nowhere is this philosophy more apparent, or more risky, than in biotechnology. Here, companies are quite literally inventing the future in a petri dish. They are using mind-bending technologies like CRISPR gene editing to tackle diseases that were once a death sentence. The risks are, of course, enormous. A promising therapy can fail in late-stage trials, wiping out years of work and hundreds of millions in investment.
But the potential rewards are equally staggering. A single successful drug can transform a company and, more importantly, the lives of millions. Investing here isn’t for the nervous. It’s a bet on the scientific process itself. It’s this very principle of patient, internal growth that underpins a collection of companies I was looking at recently, aptly named The Garage Innovators.
Of course, this approach isn’t a magic bullet. The road of innovation is littered with failed experiments and ideas that were simply ahead of their time. For every breakthrough, there are a dozen costly dead ends. This is not a strategy for impatient capital. But for investors willing to play the long game, focusing on the builders rather than the buyers could be a very interesting way to think about constructing a portfolio. After all, anyone can buy a trophy, but it takes real skill to build one from scratch.